Search

Obsessive–compulsive disorder (OCD) is an important neuropsychiatric disorder worldwide. Common treatments of OCD include serotonergic antidepressants, which can cause potentially serious side effects. We assessed the effects of Lactobacillus casei (L. casei) Shirota consumption in an animal model of OCD. OCD-like symptoms were induced in rats by the chronic injection of the D2/D3 dopamine agonist quinpirole hydrochloride. Rats were classified into five groups of 6 rats. Four groups were injected chronically with quinpirole (0.5 mg/kg, twice weekly for 5 weeks). They were fed with L. casei Shirota (109 CF/g, daily for 4 weeks) (group 1), fluoxetine (10 mg/kg, daily for 4 weeks) (group 2), combination of L. casei Shirota and fluoxetine (group 3), and normal saline (positive control group). The last group did not receive dopamine agonist and was only injected with saline (negative control group). Expression levels of brain-derived neurotrophic factor (Bdnf), solute carrier family 6 member 4 (Slc6a4), and 5-hydroxytryptamine receptor type 2A (Htr2a) were assessed in orbitofrontal cortex tissues of all rats. Behavioral tests showed improvement of OCD signs in rats treated with L. casei Shirota, fluoxetine, and a combination of drugs. Quantitative PCR analysis showed a remarkable decrease in the expression of Bdnf and an increase in the expression of Htr2a in quinpirole-treated rats. After treatment with L. casei Shirota and fluoxetine, the expression level of Bdnf was increased remarkably, whereas Htr2a expression was decreased. The current study showed the effectiveness of L. casei Shirota in the treatment of OCD in a rat model. The beneficial effects of this probiotic are possibly exerted through the modulation of serotonin-related genes expression.

Promoting general health in terms of obesity and diabetes prevention is recommended by health care systems. The objectives of this study were to isolate an efficient glucose-converting Komagataeibacter xylinus to cellulose and to evaluate the safety of the selected strain as a new generation of probiotics in the fight against obesity. Of the 97 samples, 43 K xylinus strains were isolated and evaluated for their glucose conversion rate and 5 strains were examined for probiotic activities by in vitro assays. A strain with significant performance was fed to rats in order to determine its safety status in vivo. The results revealed that the strain K.X.1 had high level of glucose conversion rate and significant survival rate in acidic pH and bile salt. No adverse clinical signs and bacterial translocation to rats’ organs were observed. The results showed that the strain of K. xylinus K.X.1 has suitable probiotic properties.

International audience

International audience